{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:21:07Z","timestamp":1787862067383,"version":"build-2784847793"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T00:00:00Z","timestamp":1682121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.farma.2023.04.006","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T08:25:12Z","timestamp":1685003112000},"page":"201-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systematic review and cost-effectiveness analysis of the treatment of post-stroke spasticity with abobotulinumtoxinA compared to physiotherapy"],"prefix":"10.1016","volume":"47","author":[{"given":"Mar\u00eda","family":"Errea Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"del Llano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Nu\u00f1o-Solin\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2023.04.006_bb0005","author":"World Health Organization"},{"issue":"10159","key":"10.1016\/j.farma.2023.04.006_bb0010","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Roth","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.farma.2023.04.006_bb0015","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0028-3843(14)60300-5","article-title":"Prevalence of spasticity following stroke and its impact on quality of life with emphasis on disability in activities of daily living. Systematic review","volume":"44","author":"Schinwelski","year":"2010","journal-title":"Neurologia i Neurochirurgia Polska"},{"key":"10.1016\/j.farma.2023.04.006_bb0020","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.toxicon.2018.01.018","article-title":"Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity \u2013 Insights from recent studies","volume":"147","author":"Wissel","year":"2018","journal-title":"Toxicon."},{"key":"10.1016\/j.farma.2023.04.006_bb0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/IJGM.S36030","article-title":"Incidence estimate and guideline-oriented treatment for post-stroke spasticity: An analysis based on German statutory health insurance data","volume":"6","author":"Egen-Lappe","year":"2013","journal-title":"Int J General Med"},{"issue":"4","key":"10.1016\/j.farma.2023.04.006_bb0030","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/16501970510027312","article-title":"Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity","volume":"37","author":"Ward","year":"2005","journal-title":"J Rehabil Med"},{"issue":"2","key":"10.1016\/j.farma.2023.04.006_bb0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/mus.25721","article-title":"Effects of repeated abobotulinumtoxinA injections in upper limb spasticity: repeat AboBoNT-A in Spasticity","volume":"57","author":"Gracies","year":"2018","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.farma.2023.04.006_bb0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.rehab.2019.06.003","article-title":"Botuloscope: 1-year follow-up of upper limb post-stroke spasticity treated with botulinum toxin","volume":"62","author":"Marque","year":"2019","journal-title":"Ann Phys Rehabil Med"},{"issue":"7","key":"10.1016\/j.farma.2023.04.006_bb0045","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2340\/16501977-0366","article-title":"Botulinum toxin A for treatment of upper limb spasticity following stroke: A multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes","volume":"41","author":"McCrory","year":"2009","journal-title":"J Rehabil Med"},{"issue":"7","key":"10.1016\/j.farma.2023.04.006_bb0050","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3390\/toxins10070253","article-title":"Early AbobotulinumtoxinA (Dysport\u00ae) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study","volume":"10","author":"Rosales","year":"2018","journal-title":"Toxins."},{"issue":"2","key":"10.1016\/j.farma.2023.04.006_bb0055","first-page":"1","article-title":"AbobotulinumtoxinA and rehabilitation vs rehabilitation alone in post-stroke spasticity: A cost-utility analysis","volume":"52","author":"Lazzaro","year":"2020","journal-title":"J Rehabil Med"},{"issue":"Suppl 2","key":"10.1016\/j.farma.2023.04.006_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1331.2010.03125.x","article-title":"International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments\u2014Introduction","volume":"17","author":"Esquenazi","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.farma.2023.04.006_bb0065","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3389\/fneur.2021.694872","article-title":"Best practices in the clinical management of progressive supranuclear palsy and corticobasal syndrome: a consensus statement of the CurePSP centers of care","volume":"12","author":"Bluett","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.farma.2023.04.006_bb0070","series-title":"Rehabilitation management of post-stroke spasticity","author":"Demetrios","year":"2017"},{"issue":"22","key":"10.1016\/j.farma.2023.04.006_bb0075","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1212\/WNL.0000000000004687","article-title":"Efficacy and safety of abobotulinumtoxinA in spastic lower limb: randomized trial and extension","volume":"89","author":"Gracies","year":"2017","journal-title":"Neurology."},{"issue":"7","key":"10.1016\/j.farma.2023.04.006_bb0080","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1177\/1545968311430824","article-title":"Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial","volume":"26","author":"Rosales","year":"2012","journal-title":"Neurorehabil Neural Repair"},{"issue":"26","key":"10.1016\/j.farma.2023.04.006_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14260","article-title":"BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A","volume":"14","author":"Shaw","year":"2010","journal-title":"Health Technol Assess"},{"issue":"10","key":"10.1016\/j.farma.2023.04.006_bb0090","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1474-4422(15)00216-1","article-title":"Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: A double-blind randomised controlled trial","volume":"14","author":"Gracies","year":"2015","journal-title":"The Lancet Neurol"},{"key":"10.1016\/j.farma.2023.04.006_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"10.1016\/j.farma.2023.04.006_bb0100","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.farma.2023.04.006_bb0105","first-page":"354","article-title":"Health outcomes during the 2008 financial crisis in Europe: systematic literature review","author":"Parmar","year":"2016","journal-title":"BMJ."},{"key":"10.1016\/j.farma.2023.04.006_bb0110","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/j.jval.2021.04.797","article-title":"PND13 Cost-effectiveness analysis on Dysport: A focus on early intervention to improve barefoot walking speed","volume":"24","author":"Moore","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.farma.2023.04.006_bb0115","first-page":"193","article-title":"An\u00e1lisis de costes del uso de toxina botul\u00ednica A en Espa\u00f1a","volume":"3","author":"de Andr\u00e9s-Nogales","year":"2014","journal-title":"Farm Hosp"},{"issue":"4","key":"10.1016\/j.farma.2023.04.006_bb0120","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s10389-019-01161-6","article-title":"Budget impact of botulinum toxin treatment for spasticity after stroke\u2014A German perspective","volume":"29","author":"Neusser","year":"2019","journal-title":"J Public Health"},{"issue":"12","key":"10.1016\/j.farma.2023.04.006_bb0125","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3390\/toxins4121415","article-title":"Cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A: results from the botulinum toxin for the upper limb after stroke (BoTULS)","volume":"4","author":"Shackley","year":"2012","journal-title":"Trial Toxins"},{"key":"10.1016\/j.farma.2023.04.006_bb0130","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/CEOR.S76141","article-title":"Budget impact analysis of botulinum toxin A therapy for upper limb spasticity in the United Kingdom","volume":"7","author":"Abogunrin","year":"2015","journal-title":"Clin Econ Outcomes Res"},{"issue":"12","key":"10.1016\/j.farma.2023.04.006_bb0135","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3390\/toxins11120707","article-title":"Botulinum toxin therapy combined with rehabilitation for stroke: a systematic review of effect on motor function","volume":"11","author":"Hara","year":"2019","journal-title":"Toxins."},{"issue":"5","key":"10.1016\/j.farma.2023.04.006_bb0140","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3390\/toxins12050315","article-title":"High dosage of botulinum toxin type A in adult subjects with spasticity following acquired central nervous system damage: where are we at?","volume":"12","author":"Intiso","year":"2020","journal-title":"Toxins."},{"issue":"4","key":"10.1016\/j.farma.2023.04.006_bb0145","article-title":"The limitations of QALY: a literature review","volume":"6","author":"Pettitt","year":"2016","journal-title":"J Stem Cell Res Ther"},{"issue":"23","key":"10.1016\/j.farma.2023.04.006_bb0150","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1136\/heartjnl-2015-308255","article-title":"QALYs in cost-effectiveness analysis: An overview for cardiologists","volume":"101","author":"Wouters","year":"2015","journal-title":"Heart."},{"key":"10.1016\/j.farma.2023.04.006_bb0155","series-title":"Cost-Effectiveness in Health and Medicine","author":"Neumann","year":"2016"},{"issue":"11","key":"10.1016\/j.farma.2023.04.006_bb0160","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3390\/toxins14110734","article-title":"AbobotulinumtoxinA doses in upper and lower limb spasticity: a systematic literature review","volume":"14","author":"Schnitzler","year":"2022","journal-title":"Toxins (Basel)"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634323000429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634323000429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:17:31Z","timestamp":1761106651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634323000429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1130634323000429"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2023.04.006","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review and cost-effectiveness analysis of the treatment of post-stroke spasticity with abobotulinumtoxinA compared to physiotherapy","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2023.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}